PPHM Share Price

Open 4.63 Change Price %
High 4.87 1 Day 0.06 1.30
Low 4.56 1 Week -0.58 -11.07
Close 4.66 1 Month 4.09 717.54
Volume 304659 1 Year 4.29 1159.46
52 Week High 5.78
52 Week Low 0.28
PPHM Important Levels
Resistance 2 4.95
Resistance 1 4.83
Pivot 4.70
Support 1 4.49
Support 2 4.37
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
TOPS 0.44 69.23%
More..
NASDAQ USA Top Gainers Stocks
TOPS 0.44 69.23%
SCHS 0.05 66.67%
ELTK 0.95 53.23%
LOCM 0.09 50.00%
SGMS 34.15 27.19%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
MTSL 0.64 20.75%
WBMD 66.10 19.77%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
CYTX 0.48 -56.76%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM)

PPHM Technical Analysis 5
As on 24th Jul 2017 PPHM Share Price closed @ 4.66 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.67 & Strong Buy for SHORT-TERM with Stoploss of 1.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
PPHM Target for July
1st Target up-side 0.67
2nd Target up-side 0.71
3rd Target up-side 0.75
1st Target down-side 0.55
2nd Target down-side 0.51
3rd Target down-side 0.47
PPHM Other Details
Segment EQ
Market Capital 78153800.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.peregrineinc.com
PPHM Address
PPHM
14282 Franklin Avenue
Tustin, CA 92780
United States
Phone: 714-508-6000
Fax: 714-838-5817
PPHM Latest News
Interactive Technical Analysis Chart Peregrine Pharmaceuticals Inc. ( PPHM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Peregrine Pharmaceuticals Inc.
PPHM Business Profile
Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is the Company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer. PGN650 is the Company's PS-targeting imaging agent that represents a potential new approach to imaging cancer. The Company is conducting three randomized Phase II trials for bavituximab in combination with standard chemotherapy for front and second-line non-small cell lung cancer and front-line pancreatic cancer. In addition to these company-sponsored trials for bavituximab, the Company has four investigator-sponsored trials looking at different treatment combinations and additional oncology indications.